Your session is about to expire
← Back to Search
VST Therapy for Kidney Transplant Infection
Study Summary
This trial will test if VST cells are safe and effective against BKV in kidney transplant recipients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- I am between 18 and 75 years old.I am taking steroids equivalent to more than 0.5 mg/kg of prednisone at the time of my T-cell transfer.I am over 18, can donate blood through leukapheresis, match the HLA criteria, am BK virus positive, meet the UW Program's donor criteria, and can consent.I have a BK virus infection that has spread beyond my kidneys.I have received an organ transplant that is not a kidney.I am experiencing acute rejection of my kidney transplant.I am HIV positive.I have received specific immune system treatments within the last 28 days.I am not pregnant, breastfeeding, and willing to use birth control if of childbearing potential.I have a BK virus infection after kidney transplant.
- Group 1: BK with VST
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Am I eligible to be an enrollee in this clinical experiment?
"This clinical trial seeks to recruit 20 individuals suffering from a communicable illness between the age of 18 and 75. To meet all criteria, applicants must be infected with BKV Nephropathy, show evidence of viremia (defined as >250 copies on qPCR) despite being administered lower immunosuppressive medication; display new or worsening symptoms regardless of said medications; provide written informed consent for their donor; and have experienced adverse effects from their immunosuppressant drugs such as dnDSA or biopsy proven rejection."
What outcomes is the research project attempting to achieve?
"This trial, monitored over a duration of one year, will investigate the Adverse Event rate within four hours following Cell Infusion. Among its secondary objectives are Overall Survival Rate (time from T-cell transfer to death or last follow-up), feasibility of BK specific T cell production on intent-to-treat basis, and amount of time required for clearance of BKV after day 0 T cell transfer as verified by two negative PCR tests made at least two weeks apart."
Are there any openings for individuals to participate in this trial?
"Affirmative, according to the information accessible on clinicaltrials.gov this medical study is actively seeking participants. This trial was first announced in December 2021 and has gone through several updates since then; now, it seeks 20 patients from one research facility."
Can potential risks be associated with BK-specific T cells from Donor Lymphocytes therapy?
"Due to the limited clinical data surrounding BK-specific T cells from Donor Lymphocytes, our team at Power assigned them a score of 1 for safety."
Does the eligibility criteria of this medical study encompass individuals over 80 years old?
"To be eligible for this clinical trial, participants must range in age from 18 to 75. In addition, there are 201 distinct trials available for minors and 613 studies suitable for those aged 65 and above."
What is the enrollment capacity of this clinical trial?
"Affirmative. Clinicaltrials.gov indicates that this clinical trial, which was initially published on December 16th 2021, is presently attempting to recruit patients. Approximately 20 individuals need to be selected from 1 particular medical centre."
Share this study with friends
Copy Link
Messenger